Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LY3884961 / Eli Lilly
PROVIDE, NCT04411654: Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease	Active, not recruiting	1/2	15	Europe, US	LY3884961, Methylprednisolone, Sirolimus, Prednisone	Prevail Therapeutics, Eli Lilly and Company	Gaucher Disease, Type 2	05/28	05/28
PROPEL, NCT04127578: Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation	Recruiting	1/2	20	Europe, US, RoW	LY3884961, Methylprednisolone, Sirolimus	Prevail Therapeutics, Eli Lilly and Company	Parkinson Disease	06/29	06/29
NCT05487599: A Clinical Trial of PR001 (LY3884961) in Patients with Peripheral Manifestations of Gaucher Disease (PROCEED)	Recruiting	1/2	15	Europe, US	LY3884961	Prevail Therapeutics, Eli Lilly and Company	Gaucher Disease, Gaucher Disease, Type 1	10/30	10/30